This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bornfeldt, K. E. Search for Related Content PubMed PubMed Citation Articles by Bornfeldt, K. E.

(Circulation Research. 2006;98:720.)
© 2006 American Heart Association, Inc.

Editorial

Nuclear Signaling in Smooth Muscle Cells

Cyclic Nucleotide Phosphodiesterase 1A Moves In

Karin E. Bornfeldt

From the Department of Pathology, University of Washington School of Medicine, Seattle.

Correspondence to Karin E. Bornfeldt, Department of Pathology, Box 357470, University of Washington School of Medicine, Seattle, WA 98195-7470. E-mail bornf@u.washington.edu

See related article, pages 777–784

Key Words: cyclic GMP • cyclic nucleotide phosphodiestaerases • cytoskeleton • editorials • proliferation • smooth muscle cell

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The second messenger cyclic GMP (cGMP) mediates signaling in the nervous system, genitourinary system, and the gastrointestinal tract. In the cardiovascular system, cGMP regulates vasorelaxation, vascular remodeling, platelet activation, and cardiac contractility. The ability of cGMP to regulate such a large number of temporally and spatially disparate processes is attributable to the many different isozymes that exist for synthesis and degradation of cGMP. These enzymes exhibit different subcellular localization and mechanisms of activation. Thus, cGMP is synthesized from GTP by both soluble and particulate forms of guanylyl cyclase. Soluble guanylyl cyclases are heterodimeric cytosolic enzymes that consist of and ß subunits. There are several isoforms of the and ß subunit, ₁ß₁ being the most abundant combination in mammalian tissues.^1–3 Soluble guanylyl cyclase is activated by nitric oxide (NO) and NO-releasing drugs. Particulate forms of guanylyl cyclase, on the other hand, are transmembrane proteins that are activated by the natriuretic peptides ANP, BNP, and CNP.⁴ Similarly, cGMP is degraded by a large number of cyclic nucleotide phosphodiesterases (PDEs). To date, 21 different PDE genes divided among 11 gene families have been identified in mammals. Most PDE families contain more than one gene, and most genes code for more than one mRNA. Although some PDE gene families hydrolyze cAMP exclusively (PDE4, PDE7, PDE8), many of these enzymes hydrolyze cGMP, or both cAMP and cGMP.⁵ PDE5 is the major cGMP-specific PDE gene family in some cell types. Other cGMP-hydrolyzing PDE gene families include PDE1, PDE2, PDE6, PDE9, PDE10, PDE11, and possibly PDE3.⁶ Any . . . [Full Text of this Article]